Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID H VESOLE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790773356
CMS profile
171721
Location
HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$104,310.30

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID H VESOLE

NPI 1790773356 · CMS profile ID 171721

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HACKENSACK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790773356?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID H VESOLE, NPI 1790773356, CMS profile ID 171721. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790773356?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID H VESOLE, NPI 1790773356, CMS profile ID 171721. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790773356?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID H VESOLE, NPI 1790773356, CMS profile ID 171721, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790773356?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $104,310.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $300.0003/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015744569 CMS
GENZYME CORPORATION $425.0003/04/2023 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061213261 CMS
Janssen Biotech, Inc. $63.6102/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716071 CMS
Janssen Biotech, Inc. $4,390.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716075 CMS
Janssen Biotech, Inc. $58.8202/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716077 CMS
Janssen Biotech, Inc. $19.6502/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716081 CMS
Janssen Biotech, Inc. $12.7502/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716083 CMS
Janssen Biotech, Inc. $675.0001/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716191 CMS
Janssen Biotech, Inc. $1,350.0001/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988716189 CMS
Amgen Inc. $3,600.0001/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020562943 CMS
Amgen Inc. $482.0901/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020562945 CMS
Amgen Inc. $125.0001/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020562947 CMS
Karyopharm Therapeutics Inc. $1,550.0001/10/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056899114 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $155,486.93 116
PY2020 $91,824.34 58
PY2021 $97,647.54 66
PY2022 $159,661.69 117
PY2023 $104,310.30 113
PY2024 $93,296.96 128
PY2025 $23,607.86 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,160.00 5
PY2025 Principal investigator $373,314.67 27
PY2024 Recipient $33,985.40 5
PY2024 Principal investigator $147,320.61 23
PY2023 Recipient $1,448.20 3
PY2023 Principal investigator $467,503.40 52
PY2022 Recipient $5,622.90 4
PY2022 Principal investigator $578,663.56 39
PY2021 Recipient $38,333.70 1
PY2021 Principal investigator $409,754.43 34
PY2020 Recipient $8,197.20 1
PY2020 Principal investigator $150,543.15 18
PY2019 Recipient $12,425.31 3
PY2019 Principal investigator $151,691.61 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $2,400.00 12/22/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143146
Principal investigator 1 GENZYME CORPORATION $52,228.98 12/15/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143142
Principal investigator 1 GENZYME CORPORATION $39,251.98 12/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143134
Principal investigator 1 GENZYME CORPORATION $45,600.00 12/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143139
Recipient PFIZER INC. $940.00 11/10/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727509
Principal investigator 1 PFIZER INC. $2,936.70 11/05/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228714431
Principal investigator 1 GENZYME CORPORATION $110,813.96 10/20/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143127
Principal investigator 1 PFIZER INC. $3,978.00 09/24/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228761674
Recipient PFIZER INC. $620.00 09/17/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726949
Principal investigator 1 PFIZER INC. $4,734.60 09/03/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228754210
Principal investigator 1 GENZYME CORPORATION $3,000.00 08/18/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
FIH SAR446523 GDPRC5D ADCC Enhanced R/R in Multiple Myeloma SC No dispute reported 06/30/2026 1226143116
Principal investigator 1 PFIZER INC. $1,528.80 08/13/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228786120
Recipient PFIZER INC. $330.00 08/05/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727751
Principal investigator 1 PFIZER INC. $3,719.30 07/25/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228782448
Principal investigator 1 PFIZER INC. $2,100.80 07/16/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228763566
Principal investigator 1 GENZYME CORPORATION $29,310.00 07/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226143092
Principal investigator 1 GENZYME CORPORATION $29,300.00 07/02/2025 Covered Recipient Teaching Hospital
Hackensack University Medical Center
FIH SAR446523 GDPRC5D ADCC Enhanced R/R in Multiple Myeloma SC No dispute reported 06/30/2026 1226143102
Principal investigator 1 PFIZER INC. $2,100.80 07/02/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228784722
Principal investigator 1 PFIZER INC. $10,439.65 06/26/2025 Non-covered Recipient Entity
Georgetown University Clinical Trials
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228777032
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 06/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175383585
Recipient PFIZER INC. $940.00 05/19/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751384
Principal investigator 1 Janssen Research & Development, LLC $364.00 05/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175383616
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 05/09/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175383636
Principal investigator 1 Janssen Research & Development, LLC $728.00 03/31/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant No dispute reported 06/30/2026 1175383578
Principal investigator 1 PFIZER INC. $3,254.85 03/26/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228797479
Principal investigator 1 PFIZER INC. $3,254.85 03/19/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228794852
Principal investigator 1 PFIZER INC. $3,254.85 02/26/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228753697
Principal investigator 1 PFIZER INC. $300.00 02/19/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228719973
Principal investigator 1 PFIZER INC. $3,254.85 02/05/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228759764
Principal investigator 1 PFIZER INC. $3,254.85 01/29/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228801306
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768932
Principal investigator 1 PFIZER INC. $3,254.85 01/08/2025 Covered Recipient Teaching Hospital
PALISADES MEDICAL CENTER
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228801578

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $5,000.00 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $5,000.00 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $5,000.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $5,000.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $5,000.00 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $5,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

6 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1126328717
PY2023 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 987500393
PY2022 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 923383085
PY2021 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 806202055
PY2020 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 729093753
PY2019 Cornerstone Specialty Network LLC $0.00 $5,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 627736439